Your gift funds CPP's Phase 1 work to build the fiscal case for Oregon Medicaid coverage of psilocybin therapy, laying the groundwork for a 2027 legislative appropriation and creating the roadmap every other state can follow.
Your gift funds:
If Oregon proves that public coverage of psilocybin therapy produces better outcomes at lower cost, it creates the roadmap for every other state.
38 states have introduced more than 300 psychedelic access bills. Every one runs into the same wall: legislators want to know what it costs, what it saves, and whether public dollars are justified. No state has answered that question.
Oregon is the only one that can. Three years of operational data. A regulatory framework no other state can match. The largest real-world evidence base in the country.
The evidence exists, scattered across clinical trials, OHA data, and OHSU's OPEN research program. No one has synthesized it into a Medicaid cost-benefit analysis. That is what CPP will do in 2026.
Identify which patient population produces the largest cost savings relative to current Medicaid spending. Treatment-resistant depression, tobacco cessation, alcohol use disorder. This analysis becomes the basis for the legislative ask.
Compile clinical trial data, Oregon real-world outcomes, and Medicaid cost data into a single policy-ready package that legislators and agency staff can act on immediately.
Map the regulatory and legislative steps required to bring psilocybin therapy into Oregon Health Plan coverage, including CCO integration, billing infrastructure, and 2027 legislative vehicles.
Build the provider and advocacy coalition needed to support a coverage push in 2027: service centers, CCOs, OHA staff, legislators, clinicians, and clients.
CPP is led by Sam Chapman, who managed the Measure 109 campaign, authored SB 303, and has 15 years of Oregon legislative advocacy experience. Senior Advisor Dr. Bruce Goldberg, founding director of the Oregon Health Authority, provides direct credibility with the agency staff and legislators who will decide whether psilocybin therapy enters Oregon Health Plan coverage.
CPP spends nine months in 2026 producing the ROI analysis, evidence synthesis, and legislative strategy needed to bring a credible $1 million Medicaid pilot appropriation to the 2027 Oregon session. This is the work your gift funds.
A $1 million Oregon legislative appropriation funds a Medicaid pilot: direct dollars for current Medicaid recipients to access psilocybin therapy, with a side-by-side comparison against existing behavioral health treatments. Phase 2 lobbyist engagement is funded separately once Phase 1 milestones are met.
A successful Oregon pilot produces a Medicaid coverage pathway, a legislative template, and a fiscal case that every state exploring psychedelic access can adopt. It proves that state-regulated psilocybin programs can function as cost-efficient tools in a state behavioral health system, independent of the medical-only frameworks most legislatures are currently pursuing. Oregon's window to establish this proof point is the 2027 session. After that, other states will move first.
CPP is raising $100,000 to fully fund Phase 1 and position the 2027 legislative campaign.
This is the analysis that breaks the fiscal note barrier for psilocybin legislation—not just in Oregon, but for every state weighing public payer coverage. It moves the field from philanthropic dependence to sustainable public funding.
Every dollar goes directly toward the ROI analysis, evidence synthesis, and legislative strategy that makes the 2027 Oregon session winnable.
To discuss CPP's Phase 1 work or explore ways to support the campaign, reach out to our founder and executive director.
The Center for Psychedelic Policy is a 501(c)(3) nonprofit. Contributions are tax-deductible to the extent allowed by law.